Paeds Vivas · rheumatology-musculoskeletal-and-sports
Juvenile dermatomyositis — branching viva
Branching viva on juvenile dermatomyositis: the clinical diagnosis of heliotrope rash and Gottron papules with proximal weakness, the classification criteria, the myositis-specific antibody phenotypes, first-line treatment with corticosteroids and methotrexate, and the prevention and management of calcinosis.
On this page
Study tools
Target exams
Examiner opening (Examiner)
You are the general paediatric registrar in the clinic. A six-year-old girl has three weeks of progressive difficulty climbing stairs, a violaceous periorbital rash with oedema, and scaly red papules over her knuckles, and her creatine kinase is 2 400 U per litre. Talk me through your unifying diagnosis and your immediate plan. [1]
Exemplar opening (Candidate)
This child has a clinical picture strongly suggestive of juvenile dermatomyositis, the commonest idiopathic inflammatory myopathy of childhood, and I would move quickly because disease activity accumulates damage and the window to prevent calcinosis is open now. The combination of a heliotrope rash, Gottron papules and symmetric proximal weakness with a raised creatine kinase is characteristic. I will confirm muscle inflammation with aldolase and lactate dehydrogenase, image the thigh muscles with magnetic resonance imaging, send a myositis-specific antibody panel, and start treatment in parallel rather than waiting for every result. [1] [2]
References4ShowHide
- [1]Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis, 2017.PMID 29079590
- [2]Bohan A, Peter JB Polymyositis and dermatomyositis (first of two parts). N Engl J Med, 1975.PMID 1090839
- [3]Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet, 2016.PMID 26645190
- [4]Hoeltzel MF, Oberle EJ, Robinson AB, et al. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep, 2014.PMID 25366934